Holen Sie sich die Stockscreener-App
98.66
0.19%
0.19
Vorhandelsmarkt:
96.86
-1.80
-1.82%
Schlusskurs vom Vortag:
$98.47
Offen:
$98.2
24-Stunden-Volumen:
1.29M
Relative Volume:
0.65
Marktkapitalisierung:
$13.08B
Einnahmen:
$1.08B
Nettoeinkommen (Verlust:
$-433.19M
KGV:
-29.01
EPS:
-3.4004
Netto-Cashflow:
$-225.09M
1W Leistung:
+6.94%
1M Leistung:
+14.19%
6M Leistung:
+4.55%
1J Leistung:
+142.29%
1-Tages-Spanne:
$96.04
$99.54
1-Wochen-Bereich:
$89.07
$100.73
52-Wochen-Spanne:
$36.36
$120.74
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
98.66 | 13.06B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
448.21 | 165.75B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
164.54 | 117.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
532.86 | 41.70B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
333.21 | 32.89B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
113.26 | 31.86B | 7.07B | 1.29B | 993.00M | 4.5355 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Bestätigt | Canaccord Genuity | Buy |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-09-25 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-28 | Fortgesetzt | BTIG Research | Buy |
| 2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
| 2022-02-24 | Bestätigt | Citigroup | Buy |
| 2022-02-24 | Bestätigt | Cowen | Outperform |
| 2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-24 | Bestätigt | SVB Leerink | Outperform |
| 2022-02-24 | Bestätigt | Stifel | Buy |
| 2022-02-24 | Bestätigt | Wells Fargo | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-11 | Eingeleitet | Stifel | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-06-12 | Eingeleitet | BTIG Research | Buy |
| 2020-02-21 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
The Cancer Test That Wall Street Is Betting On - WSJ
Guardant Health Insider Sold Shares Worth $5,016,000, According to a Recent SEC Filing - Moomoo
Guardant Health (GH) co-CEO family trust sells 50,000 shares - Stock Titan
Guardant Health co-CEO Talasaz sells $5.02 million in stock By Investing.com - Investing.com India
Guardant Health co-CEO Talasaz sells $5.02 million in stock - Investing.com
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Guardant Health (GH) Q1 2026 Earnings Transcript - AOL.com
Guardant Health CMO resigns - MSN
GH Q1 Deep Dive: Shield Volume Acceleration and Oncology Portfolio Expansion Fuel Growth - Yahoo Finance
Trading the Move, Not the Narrative: (GH) Edition - Stock Traders Daily
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health Insiders Sold US$52m Of Shares Suggesting Hesitancy - 富途牛牛
Guardant Health raises 2026 revenue outlook to $1.30B-$1.32B as Shield targets 230,000-245,000 tests - MSN
Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $135 - Moomoo
Evercore ISI Keeps an “In Line” Rating on Guardant Health, Inc. (GH) - Insider Monkey
Guardant Health, Inc. (GH) Stock Analysis: Unveiling a 36% Upside Potential in Precision Oncology - DirectorsTalk Interviews
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen - Insider Monkey
Guardant Health, Inc. (NASDAQ:GH) Q1 2026 Earnings Call Transcript - Insider Monkey
Guardant Health (GH) Gets a Buy from Canaccord Genuity - The Globe and Mail
Guardant Health Q1 2026 slides: revenue soars 48% on Shield momentum By Investing.com - Investing.com South Africa
Guardant Health : Q1 2026 Earnings Call - marketscreener.com
GH Maintained by JP Morgan -- Price Target Raised to $135 - GuruFocus
GH Maintained by Barclays -- Price Target Raised to $120 - GuruFocus
Guardant Health (GH) Announces Departure of Chief Medical Officer - GuruFocus
Guardant Health, Inc. Q1 2026 Financial Results and Analysis – Revenue, Expenses, and Comprehensive Loss Overview - Minichart
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $95 to $135 - Moomoo
Guardant Health Q1 2026 slides: revenue soars 48% on Shield momentum - Investing.com Australia
Barclays Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $120 - 富途牛牛
BofA Securities Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $135 - Moomoo
Guardant Health: Q1 Earnings Snapshot - theheraldreview.com
Guardant Health 1Q Loss/Shr 85c >GH - Moomoo
GH Stock Price, Quote & Chart | GUARDANT HEALTH INC (NASDAQ:GH) - ChartMill
Earnings call transcript: Guardant Health Q1 2026 revenue soars, EPS misses By Investing.com - Investing.com South Africa
Earnings call transcript: Guardant Health Q1 2026 revenue soars, EPS misses - Investing.com Nigeria
Guardant Health Q1 Earnings Call Highlights - Barchart.com
Guardant Health, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:GH) 2026-05-07 - Seeking Alpha
GH Financials: Income Statement, Balance Sheet & Cash Flow | Guardant Health - Stock Titan
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics - Yahoo! Finance Canada
Research Alert: Guardant Health: Testing Volume Growth Highlights Successful Q1 Results - Moomoo
Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Guardant Health Stock Sinks After Surprise Share Sale - TipRanks
Guardant Health Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Guardant Health (NASDAQ:GH) Delivers Impressive Q1 CY2026, Stock Soars - Yahoo Finance
Guardant Health Q1 Adjusted Loss Narrows, Revenue Rises; Raises Full-Year Revenue Guidance - marketscreener.com
Guardant Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Guardant Health (GH) grows revenue to $302M while managing losses and legal battles - Stock Titan
(GH) Guardant Health Expects Full Year 2026 Revenue Range $1.30B$1.32B, vs. FactSet Est of $1.27B - marketscreener.com
Guardant Health (NASDAQ:GH) Smashes Q1 Estimates, Raises Full-Year Guidance on Soaring Screening Revenue - ChartMill
Earnings Flash (GH) Guardant Health, Inc. Posts Q1 Adjusted Loss $0.45 per Share, vs. FactSet Est of $-0.45 - marketscreener.com
Earnings Flash (GH) Guardant Health, Inc. Reports Q1 Revenue $301.7M, vs. FactSet Est of $279.2M - marketscreener.com
Guardant Health (NASDAQ: GH) boosts 2026 revenue guidance on 48% Q1 jump - Stock Titan
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.16%
1.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):